Chen Zhu, Chen Xingyu, Hu Haiyang, Chen Kai, Xiao Heng, Du Chengyou, Lan Xiang
Department of Hepatobiliary Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
J Gastrointest Oncol. 2025 Feb 28;16(1):317-326. doi: 10.21037/jgo-24-691. Epub 2025 Feb 24.
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) can provide patients with large liver tumors the opportunity to undergo radical resection. However, tumor progression between the surgical stages and unsatisfactory hyperplasia of the residual liver reduces the second-stage resection rate and limit the application of ALPPS. We reported a novel modified ALPPS method that can accelerate tumor necrosis and hyperplasia of the residual liver and increase the second-stage resection rate. The data of patients who underwent the novel modified ALPPS procedure in our hospital between September 2021 and April 2024 were retrospectively analyzed. In addition to ligation of the right hepatic portal vein and liver partition during the first stage, we transected all the Glissonian pedicles of the tumor-bearing area to accelerate tumor necrosis. Ultimately, three patients underwent this novel modified ALPPS procedure. Second-stage resection was successfully performed in all these patients. Satisfactory hyperplasia was obtained in the residual liver before the second stage of surgery. The tumor-bearing area showed obvious necrosis and atrophy. The residual liver volumes of the three patients increased by 83%, 23%, and 49%, respectively. No postoperative complications or tumor recurrence was observed. This novel modified approach is safe and effective. This approach can prevent tumor progression between the surgical stages and promote compensatory liver proliferation.
联合肝脏离断和门静脉结扎分期肝切除术(ALPPS)可为患有大肝癌的患者提供接受根治性切除的机会。然而,手术分期之间的肿瘤进展以及残余肝脏增生不充分降低了二期切除率,并限制了ALPPS的应用。我们报告了一种新型改良ALPPS方法,该方法可加速肿瘤坏死和残余肝脏增生,并提高二期切除率。回顾性分析了2021年9月至2024年4月在我院接受新型改良ALPPS手术的患者数据。在第一阶段,除了结扎右肝门静脉和进行肝脏离断外,我们还横断了肿瘤区域的所有肝蒂,以加速肿瘤坏死。最终,3例患者接受了这种新型改良ALPPS手术。所有这些患者均成功进行了二期切除。在二期手术前,残余肝脏获得了满意的增生。肿瘤区域出现明显坏死和萎缩。3例患者的残余肝脏体积分别增加了83%、23%和49%。未观察到术后并发症或肿瘤复发。这种新型改良方法安全有效。该方法可防止手术分期之间的肿瘤进展,并促进肝脏代偿性增生。